The cancer vaccines market is expected to reach US$ 15,845.59 million by 2027 from US$ 4,568.82 million in 2019; the market is estimated to grow at a CAGR of 17.2% from 2020 to 2027.
The cancer vaccines assist in the treatment of the existing cancer or prevent the development of cancer; the former are known as therapeutic cancer vaccines. Several vaccines are "autologous," as they are prepared from the samples obtained from cancer patients, and such vaccines are unique to that patient. Cancer vaccines can be of two type, therapeutic vaccine and preventive vaccines. Cervarix, Gardasil, Gardasil-9, and Hepatitis B (HBV) vaccine (HEPLISAV-B) are preventive cancer vaccines, whereas, Sipuleucel-T (Provenge) are therapeutic cancer vaccines. The global cancer vaccines market is driven by factors such as increasing R&D expenditures by pharmaceutical companies, and rising government support for research activities and clinical trials. However, the high cost of drug development hinders the market growth. However, emerging markets are creating growth opportunities for the market players.
Lucrative Regional Markets for Cancer Vaccines
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Market Insights
Increase in Prevalence of Cancer Worldwide
Cancer is among the leading cause of deaths across the globe and is profoundly affecting the quality of life. Thus, cancer would be a burden on society if not diagnosed and treated on time. According to the World Health Organization (WHO), in 2018, approximately 9.6 million deaths reported across the globe were due to cancer. Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases would be diagnosed in the US. Approximately, 1.9 million new cancer cases and 693,000 cancer deaths were recorded in 2018, in North America. Prostate cancers are the most commonly diagnosed cancers among males in North America; however, breast cancer remains the leading cancer in females. As per the estimations by the American Cancer Society, breast cancer is the most common type of cancer in the US as it caused morbidity in ~234,087 people and lead to 41,904 deaths in 2018. Further, ~276,480 new cases are expected in the country in 2020. As per the Globocan 2019 report, in Germany, the total number of breast cancer cases in 2018 was 71,888, and the disease lead to ~19,376 deaths in that year. Additionally, lung cancer remains the most common cause of death in both sexes. It is estimated that the number of new cases of cancer incidence is 439.2 per 100,000 men and women per year. According to the National Health Profile, the cases of common cancers, including cervical, oral, and breast cancers have increased by 324% in India between 2017 and 2018.
Technology-Based Insights
On the basis of technology, the cancer vaccines market has been segmented into dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, and viral vector cancer vaccines. The recombinant cancer vaccines segment held the largest share of the market in 2019, and it is further anticipated to register the highest CAGR in the market during the forecast period.
Cancer Vaccines Market, by Technology – 2018 and 2027
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Type-Based Insights
The cancer vaccines market, by type, is segmented into preventive cancer vaccines and therapeutic cancer vaccines. The preventive cancer vaccines segment held a larger share of the market in 2019, and it is anticipated to register a higher CAGR in the market during the forecast period.
Indication-Based Insights
The cancer vaccines market, by indication, is segmented into cervical cancer, prostate cancer, and other indications. The cervical cancer segment held the largest share of the market in 2019, and the market for this segment is anticipated to witness the highest CAGR during the forecast period.
End User-Based Insights
The cancer vaccines market, by end user, is segmented into pediatrics and adults. The pediatrics segment held a larger share of the market in 2019, and the same segment is anticipated to register a higher CAGR of 17.4% during the forecast period.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Cancer Vaccines Market: Strategic Insights
Market Size Value in US$ 4,568.82 Million in 2019 Market Size Value by US$ 15,845.59 Million by 2027 Growth rate CAGR of 17.2% from 2020-2027 Forecast Period 2020-2027 Base Year 2020
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Cancer Vaccines Market: Strategic Insights
| Market Size Value in | US$ 4,568.82 Million in 2019 |
| Market Size Value by | US$ 15,845.59 Million by 2027 |
| Growth rate | CAGR of 17.2% from 2020-2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2020 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios; these strategies help them meet the growing consumer demand. Collaboration is one of the major strategies adopted by the cancer vaccines market players to enlarge customer base worldwide, which also permits them to maintain their brand name globally.
Global Cancer Vaccines Market – by Technology
- Dendritic Cells Cancer Vaccines
- Recombinant Cancer Vaccines
- Antigen Cancer Vaccines
- Whole Cell Cancer Vaccines
- Viral Vector Cancer Vaccines
Global Cancer Vaccines Market – by Type
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccine
Global Cancer Vaccines Market – by Indication
- Cervical Cancer
- Prostate Cancer
- Other Indications
Global Cancer Vaccines Market – by End User
- Pediatrics
- Adults
Cancer Vaccines Market – by Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of Asia Pacific
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East and Africa
- South and Central America
- Brazil
- Argentina
- Rest of South America
Company Profiles
- CSL Limited
- ADURO BIOTECH INC.
- Astellas Pharma Inc.
- Merck & Co., Inc.
- Sanofi
- Bristol-Myers Squibb Company
- Glaxosmithkline Plc.
- Dendreon
- ASTRAZENECA PLC.
- OSE Immunotherapeutics
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Technology , Type , Indication , End User and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, RoAPAC, RoE, RoMEA, RoSCAM, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Cancer Vaccines Market – By Technology
1.3.2 Global Cancer Vaccines Market – By Type
1.3.3 Global Cancer Vaccines Market – By Indication
1.3.4 Global Cancer Vaccines Market – By End-User
1.3.5 Global Cancer Vaccines market – By Geography
2. Cancer Vaccines Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Cancer Vaccines Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe – PEST Analysis
4.2.3 Asia Pacific – PEST Analysis
4.2.4 Middle East and Africa (MEA) – PEST Analysis
4.2.5 South and Central America (SCAM) – PEST Analysis
4.3 Expert Opinions
5. Cancer Vaccines Market– Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Increase in Prevalence of Cancer Worldwide
5.1.2 Initiatives Taken by Global Health Research Organizations and Key Players for Cancer Vaccines
5.2 Key Market Restraints
5.2.1 Less Number of Commercially Available Vaccines for Treatment of Cancer
5.2.2 Higher Cost of Cancer Vaccines
5.3 Key Market Opportunities
5.3.1 Emerging Markets in Developing Countries
5.4 Future Trends
5.4.1 Growing Research and Development Activities
5.5 Impact analysis
6. Cancer Vaccines Market – Global Analysis
6.1 Global Cancer Vaccines Market Revenue Forecast and Analysis
6.2 Global Cancer Vaccines Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players
7. Cancer Vaccines Market – By Technology
7.1 Overview
7.2 Cancer Vaccines Market, by Technology, 2019 and 2027 (%)
7.3 Dendritic Cells Cancer Vaccine
7.3.1 Overview
7.3.2 Dendritic Cells Cancer Vaccines : Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Recombinant Cancer Vaccines
7.5.1 Overview
7.5.2 Recombinant Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
7.6 Antigen Cancer Vaccines
7.6.1 Overview
7.6.2 Antigen Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
7.7 Whole Cell Cancer Vaccines
7.7.1 Overview
7.7.2 Whole Cell Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
7.8 Viral Vector Cancer Vaccines
7.8.1 Overview
7.8.2 Viral Vector Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
8. Cancer Vaccines Market Analysis – By Type
8.1 Overview
8.2 Cancer Vaccines Market Revenue Share, by Type (2019 and 2027)
8.3 Preventive Cancer Vaccines
8.3.1 Overview
8.3.2 Preventive Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Therapeutic Cancer Vaccines
8.4.1 Overview
8.4.2 Therapeutic Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
9. Cancer Vaccines Market Analysis – By Indication
9.1 Overview
9.2 Cancer Vaccines Market Revenue Share, by Indication (2019 and 2027)
9.3 Cervical Cancer
9.3.1 Overview
9.3.2 Cervical Cancer: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Prostate Cancer
9.4.1 Overview
9.4.2 Prostate Cancer: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
9.5 Other Indications
9.5.1 Overview
9.5.2 Other Indications: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
10. Cancer Vaccines Market Analysis – By End Use
10.1 Overview
10.2 Cancer Vaccines Market Revenue Share, by End Use (2019 and 2027)
10.3 Pediatrics
10.3.1 Overview
10.3.2 Pediatrics: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
10.4 Adults
10.4.1 Overview
10.4.2 Adults: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
11. Cancer Vaccines Market Analysis And Forecasts To 2027 Geographical Analysis
11.1 North America: Cancer Vaccines Market
11.1.1 Overview
11.1.2 North America: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.1.3 North America: Cancer Vaccines Market, by Technology, 2018–2027 (USD Million)
11.1.4 North America: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.1.5 North America: Cancer Vaccines Market, by Indication, 2018–2027 (USD Million)
11.1.6 North America: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.1.7 North America: Cancer Vaccines Market, by Country, 2019 & 2027 (%)
11.1.8 US: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.1 US: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.2 US: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.1.8.3 US: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.1.8.4 US: Cancer Vaccines Market, by Technology2018–2027 (USD Million)
11.1.8.5 US: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.1.9 Canada: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 Canada: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 Canada: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.1.9.3 Canada: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.1.9.4 Canada: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.1.9.5 Canada: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.1.10 Mexico: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 Mexico: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 Mexico: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.1.10.3 Mexico: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.1.10.4 Mexico: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.1.10.5 Mexico: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.2 Europe: Cancer Vaccines Market
11.2.1 Overview
11.2.2 Europe: Cancer Vaccines Market - Revenue and Forecast to 2027 (USD Million)
11.2.3 Europe: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.2.4 Europe: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.2.5 Europe: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.2.6 Europe: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.2.7 Europe: Cancer Vaccines Market, by Country, 2018 & 2027 (%)
11.2.8 Germany: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.2.8.1 Germany: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.2.8.2 Germany: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.2.8.3 Germany: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.2.8.4 Germany: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.2.8.5 Germany: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.2.9 UK: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.2.9.1 UK: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.2.9.2 UK: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.2.9.3 UK: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.2.9.4 UK: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.2.9.5 UK: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.2.10 France: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.2.10.1 France: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.2.10.2 France: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.2.10.3 France: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.2.10.4 France: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.2.10.5 France: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.2.11 Spain: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.2.11.1 Spain: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.2.11.2 Spain: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.2.11.3 Spain: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.2.11.4 Spain: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.2.11.5 Spain: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.2.12 Italy: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.2.12.1 Italy: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.2.12.2 Italy: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.2.12.3 Italy: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.2.12.4 Italy: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.2.12.5 Italy: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.3 Asia Pacific: Cancer Vaccines Market
11.3.1 Overview
11.3.2 Asia Pacific: Cancer Vaccines Market - Revenue and Forecast to 2027 (USD Million)
11.3.3 Asia Pacific: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.3.4 Asia Pacific: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.3.5 Asia Pacific: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.3.6 Asia Pacific: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.3.7 Asia Pacific: Cancer Vaccines Market, by Country, 2018 & 2027 (%)
11.3.8 China: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.3.8.1 China: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.3.8.2 China: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.3.8.3 China: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.3.8.4 China: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.3.8.5 China: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.3.9 Japan: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.3.9.1 Japan: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.3.9.2 Japan: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.3.9.3 Japan: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.3.9.4 Japan: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.3.9.5 Japan: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.3.10 India: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.3.10.1 India: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.3.10.2 India: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.3.10.3 India: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.3.10.4 India: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.3.10.5 India: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.3.11 South Korea: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.3.11.1 South Korea: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.3.11.2 South Korea: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.3.11.3 South Korea: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.3.11.4 South Korea: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.3.11.5 South Korea: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.3.12 Australia: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.3.12.1 Australia: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.3.12.2 Australia: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.3.12.3 Australia: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.3.12.4 Australia: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.3.12.5 Australia: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.4 Middle East & Africa: Cancer Vaccines Market
11.4.1 Overview
11.4.2 Middle East & Africa: Cancer Vaccines Market - Revenue and Forecast to 2027 (USD Million)
11.4.3 Middle East & Africa: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.4.4 Middle East & Africa: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.4.5 Middle East & Africa: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.4.6 Middle East & Africa: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.4.7 Middle East & Africa: Cancer Vaccines Market Share by Country – 2019 & 2027, (%)
11.4.8 Saudi Arabia: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.4.8.1 Saudi Arabia: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.4.8.2 Saudi Arabia: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.4.8.3 Saudi Arabia: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.4.8.4 Saudi Arabia: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.4.8.5 Saudi Arabia: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.4.9 UAE: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.4.9.1 UAE: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.4.9.2 UAE: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.4.9.3 UAE: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.4.9.4 UAE: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.4.9.5 UAE: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.4.10 South Africa: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
11.4.10.1 South Africa: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.4.10.2 South Africa: Cancer Vaccines Market, by Type, 2018–2027 (USD Million)
11.4.10.3 South Africa: Cancer Vaccines Market, by Indication 2018–2027 (USD Million)
11.4.10.4 South Africa: Cancer Vaccines Market, by Technology 2018–2027 (USD Million)
11.4.10.5 South Africa: Cancer Vaccines Market, by End User, 2018–2027 (USD Million)
11.5 South and Central America: Cancer Vaccines Market
11.5.1 Overview
11.5.2 South and Central America: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.5.3 South and Central America Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
11.5.4 South and Central America Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
11.5.5 South and Central America Cancer Vaccines Market, by Technology – Revenue and Forecast to 2027 (USD Million)
11.5.6 South and Central America Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.5.7 South and Central America: Cancer Vaccines Market, by Country, 2019 & 2027 (%)
11.5.8 Brazil: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.5.8.1 Brazil: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.5.8.2 Brazil Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
11.5.8.3 Brazil Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
11.5.8.4 Brazil Cancer Vaccines Market, by Technology – Revenue and Forecast to 2027 (USD Million)
11.5.8.5 Brazil Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
11.5.9 Argentina: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.5.9.1 Argentina: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
11.5.9.2 Argentina Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
11.5.9.3 Argentina Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
11.5.9.4 Argentina Cancer Vaccines Market, by Technology – Revenue and Forecast to 2027 (USD Million)
11.5.9.5 Argentina Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
12. Impact Of COVID-19 Pandemic On Global Cancer Vaccines Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact Assessment of COVID-19 Pandemic
12.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
12.4 Rest of World: Impact Assessment of COVID-19 Pandemic
13. Cancer Vaccines Market – Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Company Profiles
14.1 CSL Limited
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 ADURO BIOTECH INC.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Astellas Pharma Inc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bristol-Myers Squibb Company
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 GlaxoSmithKline plc.
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Dendreon
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AstraZeneca
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Merck & Co., Inc.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Sanofi (Sanofi Pasteur)
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 OSE Immunotherapeutics
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 2. North America Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 3. North America Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 4. North America Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 5. Estimated Number of New Cancer Cases and Deaths, US, 2020
Table 6. US Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 7. US Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 8. US Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 9. US Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 10. Canada Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 11. Canada Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 12. Canada Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 13. Canada Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 14. Mexico Incidence, Mortality and Prevalence by cancer site in 2018
Table 15. Mexico Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 16. Mexico Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 17. Mexico Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 18. Mexico Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 19. Europe Cancer Vaccines Market, by Type– Revenue and Forecast to 2027 (USD Million)
Table 20. Europe Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 21. Europe Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 22. Europe Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 23. Incidence, Mortality and Prevalence by cancer site, 2018, Germany
Table 24. Germany Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 25. Germany Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 26. Germany Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 27. Germany Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 28. UK Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 29. UK Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 30. UK Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 31. UK Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 32. Incidence, Mortality and Prevalence by cancer site, 2018, France
Table 33. France Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 34. France Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 35. France Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 36. France Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 37. Incidence, Mortality and Prevalence by cancer site, 2018, Spain
Table 38. Spain Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 39. Spain Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 40. Spain Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 41. Spain Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 42. Incidence, Mortality and Prevalence by cancer site, 2018, Italy
Table 43. Italy Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 44. Italy Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 45. Italy Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 46. Italy Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 47. Asia Pacific Cancer Vaccines Market, by Type– Revenue and Forecast to 2027 (USD Million)
Table 48. Asia Pacific Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 49. Asia Pacific Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 50. Asia Pacific Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 51. China Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 52. China Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 53. China Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 54. China Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 55. Japan Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 56. Japan Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 57. Japan Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 58. Japan Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 59. India Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 60. India Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 61. India Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 62. India Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 63. South Korea Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 64. South Korea Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 65. South Korea Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 66. South Korea Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 67. Incidence, Mortality and Prevalence by cancer site, Australia, 2018
Table 68. Australia Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 69. Australia Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 70. Australia Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 71. Australia Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 72. Middle East & Africa Cancer Vaccines Market, by Type– Revenue and Forecast to 2027 (USD Million)
Table 73. Middle East & Africa Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 74. Middle East & Africa Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 75. Middle East & Africa Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 76. Saudi Arabia Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 77. Saudi Arabia Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 78. Saudi Arabia Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 79. Saudi Arabia Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 80. UAE Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 81. UAE Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 82. UAE Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 83. UAE Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 84. South Africa Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 85. South Africa Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 86. South Africa Cancer Vaccines Market, by Technology– Revenue and Forecast to 2027 (USD Million)
Table 87. South Africa Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 88. South and Central America Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 89. South and Central America Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 90. South and Central America Cancer Vaccines Market, by Technology – Revenue and Forecast to 2027 (USD Million)
Table 91. South and Central America Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 92. Brazil Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 93. Brazil Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 94. Brazil Cancer Vaccines Market, by Technology – Revenue and Forecast to 2027 (USD Million)
Table 95. Brazil Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 96. Argentina Cancer Vaccines Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 97. Argentina Cancer Vaccines Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 98. Argentina Cancer Vaccines Market, by Technology- Revenue and Forecast to 2027 (USD Million)
Table 99. Argentina Cancer Vaccines Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 100. Organic Developments Done By Companies
Table 101. Inorganic Developments Done By Companies
Table 102. Glossary of Terms, Cancer Vaccines Market
LIST OF FIGURES
Figure 1. Cancer Vaccines Market Segmentation
Figure 2. Cancer Vaccines Market Segmentation, By Region
Figure 3. Cancer Vaccines Market Overview
Figure 4. Recombinant Cancer Vaccines Segment Held Largest Share of Cancer Vaccines Market
Figure 5. APAC to Show Significant Growth During Forecast Period
Figure 6. Cancer Vaccines Market, by Geography (US$ Million)
Figure 7. Global Cancer Vaccines Market – Leading Country Markets (US$ Million)
Figure 8. Global Cancer Vaccines Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Asia Pacific PEST Analysis
Figure 12. Middle East and Africa (MEA) PEST Analysis
Figure 13. South and Central America (SCAM) PEST Analysis
Figure 14. Cancer Statistics, 2020
Figure 15. Cancer Vaccines Market Impact Analysis of Driver and Restraints
Figure 16. Global Cancer Vaccines Market – Revenue Forecast And Analysis – 2019- 2027
Figure 17. Market Positioning Of Key Players In Global Cancer Vaccines Market
Figure 18. Cancer Vaccines Market, by Technology, 2019 and 2027 (%)
Figure 19. Dendritic Cells Cancer Vaccines : Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. Recombinant Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. Antigen Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 22. Whole Cell Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 23. Viral Vector Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 24. Cancer Vaccines Market Revenue Share, by Type (2019 and 2027)
Figure 25. Preventive Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 26. Therapeutic Cancer Vaccines: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 27. Cancer Vaccines Market Revenue Share, by Indication (2019 and 2027)
Figure 28. Cervical Cancer: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 29. Prostate Cancer: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 30. Other Indications: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 31. Cancer Vaccines Market Revenue Share, by End Use (2019 and 2027)
Figure 32. Pediatrics: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 33. Adults: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 34. North America: Cancer Vaccines Market, by Key Country – Revenue (2019) (USD Million)
Figure 35. North America Cancer Vaccines Market Revenue and Forecast to 2027 (USD Million)
Figure 36. North America: Cancer Vaccines Market, by Country, 2019 & 2027 (%)
Figure 37. US: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 38. Canada: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 39. Mexico: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 40. Europe: Cancer Vaccines Market, by Key Country – Revenue (2019) (USD Million)
Figure 41. Europe Cancer Vaccines Market Revenue and Forecast to 2027 (USD Million)
Figure 42. Europe: Cancer Vaccines Market, by Country, 2018 & 2027 (%)
Figure 43. Germany: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 44. UK: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 45. France: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 46. Spain: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 47. Italy: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 48. Asia Pacific: Cancer Vaccines Market, by Key Country – Revenue (2019) (USD Million)
Figure 49. Asia Pacific Cancer Vaccines Market Revenue and Forecast to 2027 (USD Million)
Figure 50. China: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 51. Japan: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 52. India: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 53. South Korea: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 54. Australia: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 55. Middle East & Africa: Cancer Vaccines Market, by Key Country – Revenue (2019) (USD Million)
Figure 56. Middle East & Africa Cancer Vaccines Market Revenue and Forecast to 2027 (USD Million)
Figure 57. Middle East & Africa: Cancer Vaccines Market Share by Country – 2019 & 2027, (%)
Figure 58. Saudi Arabia: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 59. UAE: Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
Figure 60. South Africa: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 61. South and Central America: Cancer Vaccines Market, by Key Country – Revenue (2019) (USD Million)
Figure 62. South and Central America Cancer Vaccines Market Revenue and Forecast to 2027 (USD Million)
Figure 63. South and Central America: Cancer Vaccines Market, by Country, 2019 & 2027 (%)
Figure 64. Brazil: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 65. Argentina: Cancer Vaccines Market – Revenue and Forecast to 2027 (USD Million)
Figure 66. Impact of COVID-19 Pandemic in North American Country Markets
Figure 67. Impact of COVID-19 Pandemic in Europe Country Markets
Figure 68. Impact of COVID-19 Pandemic in Asia-Pacific Country Markets
Figure 69. Impact of COVID-19 Pandemic in Rest of World Country Markets
Figure 70. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies - Cancer Vaccines Market
- CSL Limited
- ADURO BIOTECH INC.
- Astellas Pharma Inc.
- Merck & Co. Inc.
- Sanofi
- Bristol-Myers Squibb Company
- Glaxosmithkline Plc.
- Dendreon
- ASTRAZENECA PLC.
- OSE Immunotherapeutics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Cancer Vaccines Market
Sep 2020
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2020
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Sep 2020
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Sep 2020
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2020
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2020
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Sep 2020
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Sep 2020
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)